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Table 1.
BMT
Group
Path-
ology
Index
BALF Analysis
Total
Cells
( 106)
macs
( 106)
CD8
T Cells
( 103)
GR1
Cells
( 103)
Protein
(g/ml)
TNF
(pg/ml)
Syngeneic 0.7  0.3 0.72  0.15 0.69  0.14 7.2  1.5 7.2  1.5 247  38 0  0
Allo
CCR1/ 5.2  0.8 2.6  0.6 1.9  0.5 473.2  69.3 87.3  14.3 517  58 24.6  1.4
Allo
CCR1/ 2.7  0.6* 1.1  0.1* 0.82  0.1 68.8  7.0** 15.3  1.6** 320  51* 1.0  0.6*
*p 
 0.05; **p 
 0.01; p  0.06.
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REVERSAL OF SEVERE GRAFT-VERSUS-HOST DISEASE AFTER NON-
MYELOABLATIVE MATCHED UNRELATED DONOR STEM CELL TRANS-
PLANT BY INFUSION OF BACKUP AUTOLOGOUS PERIPHERAL BLOOD
STEM CELLS
Khan, S.A.; Moreb, J.S. University of Florida College of Medicine,
Gainesville, FL.
Acute graft vs. host disease (GVHD) is major concern in stem cell
transplantation and is associated with signiﬁcant morbidity and mor-
tality. The incidence of grade II-IV acute GVHD is 78% and grade
III-IV is 36% afterHLAmatched unrelated donor (MUD) transplant.
We report a successful use of infusion of autologous peripheral blood
stem cells to treat severe, refractory grade 4 GVHD after a non-
myeloablative MUD transplant. Patient was a 55 years old white
female with non-secretory MM presenting with pathological fracture
of her arm. She was initially treated with VAD and then hyper-CVAD
chemotherapy and achieved partial remission (PR). Subsequently, she
underwent autologous peripheral blood stem cell transplant (PB-
SCT). She progressed 2 months after autologous PBSCT and became
refractory to Thalidomide as well as chemotherapy combination of
CCNU, VP-16, Cytoxan and prednisone. Therefore, she underwent
a non-myeloablative MUD PBSCT after conditioning with Fludara-
bine, ATG and Busulfan. Post transplant evaluation revealed persis-
tent disease with 60% plasma cells and mixed chimerism with 91%
male donor cells, so immunosuppressive therapy was tapered. Two
weeks later she developed severe grade 3 GVHD involving skin and
gut which progressed to grade 4GVHD and was refractory to therapy
with FK506, Steroids, Cellcept, Daclizumab, Remicade and Thalid-
omide. She developed severe malabsorption with albumin as low as
1.6. We gave her cyclophosphamide followed by backup autologous
stem cells in order to stop the GVHD by creating “host-versus-graft
effect”. On day90 she received 10 106/kg CD34 cells and 1.4
107/KG CD3 cells. Four weeks later she still had 99% donor chi-
merism with no signiﬁcant change in her GVHD symptoms and
therefore she was given 2nd infusion of 42 106/kg CD34 cells and
5.7  107/kg CD3 cells. Subsequently, she recovered slowly from
her GVHD and was discharged after 3 months of hospitalization.
Currently she is 2.5 years post transplant without any immunosup-
pressive therapy and most recent BM test showed 100% donor chi-
merism and stable MM with 10% plasma cells. This case demon-
strates feasibility of infusion of autologous stem cells to control
refractory GVHD. A similar case was previously reported (Ricordi et
al, Cell Transplantation 1994;3:187). The mechanism for such effect
is not clear but may involve development of tolerance of donor T
lymphocytes vs. host without inhibiting GVL effect or causing mixed
chimerism.
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CARDIAC MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE
Gilman, A.L.1; Rackley, C.2; Goldman, F.3; Serrano, A.4; Chan, K.W.5;
Schultz, K.R.6 1. University of North Carolina School of Medicine,
Chapel Hill, NC; 2. Children’s Memorial Hospital, Chicago, IL; 3.
University of Iowa, Iowa City, IA; 4. Children’s Mercy Hospital, Kansas
City, MO; 5. M.D. Anderson Cancer Center, Houston, TX; 6. British
Columbia Children’s Hospital, Vancouver, BC, Canada.
Graft-versus-host disease (GVHD) is a major cause of morbidity
and mortality after bone marrow transplantation. Well-docu-
mented manifestations of GVHD include dermatologic, gastroin-
testinal, hepatic, pulmonary, musculoskeletal, and hematologic
manifestations and sicca syndrome. To date, the heart has only
rarely been reported to be a target of GVHD. We report 11
patients who developed bradycardia, coronary artery disease, or
cardiomyolysis in association with acute or chronic GVHD. Eight
patients were male and 3 were female. Patients were 4 months-19
years old (median 12 yrs). Three patients received post-transplant
immunotherapy. The patient with Fanconi anemia/AML received
IL-2 for recurrent leukemia and two recipients of T cell-depleted
grafts received DLI, one for relapse and one for graft rejection.
Regarding possible risk factors, six patients had received total body
irradiation and ﬁve patients had received anthracyclines prior to
transplant. Other possible causes for heart block and bradycardia
including electrolyte abnormalities and medications were excluded.
Of eight patients with bradycardia, seven had resolution of brady-
cardia (including heart block and sinus node failure) and one had
improvement with increased immunosuppression. Three patients
had a recurrence of bradycardia and GVHD following weaning of
immunosuppression. The severity of these manifestations ranged
from asymptomatic to fatal. The incidence of cardiac manifesta-
tions was estimated at 9.3%. TBI and prior anthracycline therapy
did not seem to be signiﬁcant risk factors because approximately
half of patients had not received either. The majority of patients
had alternative donors and 3 had post-transplant immunotherapy.
Although uncommon, it is important to recognize these cardiac
manifestations as they may reﬂect GVHD activity and may be
reversible by increasing immunosuppression.
Cardiac Manifestations of GVHD
Age Disease
Stem Cell
Source GVHD
Cardiac
Manifest-
ation
HR during
Bradycardia
Normal
HR for
Age
Cardiac
Outcome
4 mo SCID Haplo
father
BM
Hyper-
acute
&
chronic
Complete
heart
block
30–40’s 90–140’s Resolved
w/
MP/
CSA
2 yr Fanconi,
AML
MSD BM Atypical,
after
IL-2
for
GVL
Sinus node
failure
30–40’s 90–140’s Resolved
w/
MP/
Tac
18 mo Wiskott-
Aldrich
5/6 MUD
cord
Acute &
chronic
Bradycardia 50–90’s 90–140’s Resolved
w/
MP/
HCQ
21 mo CID 4/6 MUD
cord
Acute &
chronic
Bradycardia 50–80’s 90–140’s Improved
w/
MP/
Pento-
ostatin
13 yr Refractory
LCL
MSD
PBSC
Acute &
chronic
Bradycardia 50’s 60–110 Resolved
w/
MP
17 yr ALL, CR4 6/6 MUD
PBSC
Acute Bradycardia 50’s 60–110 Resolved
w/
MP/
Zena-
pax
12 yr ALL, CR3 Haplo
mother
PBSC
Acute &
chronic
Bradycardia 50–60’s,
low 40
60–110 Resolved
w/
MP
13 yr MDS,
AML
Haplo
mother
PBSC
Acute &
chronic
Bradycardia 50–60’s 60–110 Resolved
w/
MP
18 yr ALL, CR3 MSD
PBSC
Acute &
chronic
Cardiomy-
olysis
— — Sudden
death
19 yr AML,
relapse
MSD BM Acute &
chronic
Coronary
arterioscler-
osis
— — Sudden
death
25 mo Wiskott-
Aldrich
6/6 MUD
BM
Acute &
chronic
Coronary
arterioscler-
osis
— — Sudden
death
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RELATIONSHIP BETWEEN RACE AND RISK OF ACUTE GRAFT-VERSUS-
HOST DISEASE
Klumpp, T.R.; Jillella, A.P.; Ulicny, J.A.; Emmons, R.V.B.; Mangan,
K.F. Fox Chase-Temple BMT Program, Philadelphia, PA.
Several groups have reported an increased incidence of acute
GVHD among African-American transplant recipients. However,
informal communications with other BMT teams suggest that
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these reports may be the result of publication bias, i.e., it appears
that multiple groups have looked at this issue, but only those
groups that have found a signiﬁcant relationship, potentially as a
result of random chance, have reported their ﬁndings. To further
investigate this question we developed a multivariate logistic re-
gression model for factors predictive of acute GVHD based on a
series 167 patients, including 18 African-Americans, who under-
went allogeneic BMT at our institution between January 1, 1992
and May 30, 2004. Factors examined in the multivariate model
included age, CD34 dose, CD3 dose, sex mismatch pattern (fe-
male-to-male vs other), category of conditioning regimen (full-
dose vs reduced-dose), presence or absence of an antigen-level
HLA mismatch, type of donor (related vs unrelated), stem cell
source (marrow vs PBSC), and race (African-American vs Cauca-
sian). It was not possible to separate out the potential effect of the
GVHD prophylactic regimen because our data set is characterized
by a very strong correlation between type of GVHD prophylactic
regimen and category of conditioning regimen. We observed a
univariate trend toward an increased incidence of Grade 3 or
higher acute GVHD among African Americans (39% vs 21%, p 
0.13). Race was not independently predictive of acute GVHD in
the multivariate model, although the statistical power of the model
to detect this relationship was limited due to the fact that only 18
African Americans were included in the series. Interestingly,
among patients transplanted since 1996, there was a statistically
signiﬁcant (univariate) increase in the incidence of grade 3 or
higher acute GVHD among African Americans (64% vs 25%, p 
0.01) but also a parallel disparity in the incidence of HLA-mis-
matched transplantation (27% vs 6%, p  0.036) such that race
remained non-contributory in the multivariate model. We con-
clude that the purported relationship between race and acute
GVHD may be less strong that has been previously reported due to
publication bias and/or to an increased incidence of HLA-mis-
matched transplant in this population. Further examination of this
issue using larger data sets appears warranted.
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EXTRACORPOREAL PHOTOCHEMOTHERAPY FOR (ECP) THE TREAT-
MENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
Couriel, D.R.; Hosing, C.; Anderlini, P.; Ippoliti, C.; Hsu, Y.; Neu-
mann, J.; De Lima, M.J.; Ghosh, S.; Rhodes, B.; Saliba, R.; Champlin,
R.; Donato, M. University of Texas M.D. Anderson Cancer Center,
Houston, TX.
Introduction: Chronic graft-versus-host disease (cGVHD) is a
major cause of long term morbidity and mortality following allo-
geneic hematopoietic stem cell transplant (HSCT). Beyond the
combination of steroids and calcineurin inhibitors, a variety of
immunosuppressive methods have been used to manage this con-
dition, most of them of limited efﬁcacy and steroid-sparing capac-
ity. ECP is becoming increasingly used in the treatment of acute
and chronic GVHD, with promising preliminary data. Methods:
Retrospective evaluation of all ECP procedures performed be-
tween 1/30/98 and 10/2/92 in patients with GVHD occurring after
day 100. Patients were considered evaluable for response when
they were treated with ECP for at least 1 month, without the
addition of any further immunosuppression. Complete (CR) and
partial responses (PR) had a minimal duration of 2 weeks. Results:
A total of 82 patients with chronic GVHD were analyzed. The
median age was 40 (5–70), and the donor origin was matched
sibling (48, 59%), matched unrelated (24, 29%) or mismatched
(10) HSCT. Most of them received tacrolimus-based prophylaxis
(74, 90%) and had a history of acute GVHD (64, 78%). Most
patients were on steroids (64) and had received a median of 2 (1–6)
treatments prior to ECP. Out of 82 patients, only 51 were evalu-
able for response, and the remainder received further immunosup-
pression within a month from the start of ECP (30), or lacked
documentation (1). The CR/PR rate for evaluable patients was
82% (n 42). Thirty-four patients (67%) had skin involvement
and the majority (32, 94%) responded to ECP. All types of skin
involvement (lichenoid, scleroderma, mixed, acute-appearing) re-
sponded to therapy. ECP also demonstrated activity in visceral
GVHD, with response rates of (15, 88%) and (6, 67%) respec-
tively. The CR/PR rate for oral GVHD was 100% (n 6), and for
ocular GVHD 75% (n 3). Of 51 patients, 32 required further
immunosuppression for control of their GVHD. Since initiation of
ECP, the overall survival for the whole group was 37%, with a
median survival of 10 months. Conclusions: In this heavily pre-
treated group of patients with chronic GVHD, the response to
ECP seems promising in all organs, including GVHD of the lung
and the liver. The prospective and systematic evaluation of the role
of ECP in the management of GVHD is warranted.
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SUBEROYLANILIDE HYDROXAMIC ACID MODULATES THE INNATE AND
ALLOSTIMULATORY RESPONSES OF DENDRITIC CELLS AND REGU-
LATES EXPERIMENTAL ACUTE GRAFT-VERSUS-HOST DISEASE
Reddy, P.1; Maeda, Y.1; Lowler, K.1; Liu, C.2; Dinarello, C.3; Ferrara,
J.L.M.1 1. University of Michigan Comprehensive Cancer Center, Ann
Arbor, MI; 2. University of Florida College of Medicine, Gainesville, FL;
3. University of Colorado Health Sciences Center, Denver, CO.
Dendritic cells modulate the innate (via Toll like receptors-
TLRs) and the allostimulatory immune responses. Suberoylanilide
hydroxamic acid (SAHA) is an anti-tumor agent that also exhibits
potent anti-inﬂammatory properties. We investigated the effect of
SAHA on modulating DC functions. Pre-incubation of BM de-
rived DCs with 100 nM-500 nM concentrations of SAHA (s-DCs)
signiﬁcantly reduced the secretion of TNF- and IL-6 upon TLR
stimulation with lipopolysaccharide (TLR-4), peptidoglycan
(TLR-2), poly IC (TLR-3) and CpG (TLR-9). Pre-treatment of
DCs with SAHA signiﬁcantly reduced the proliferation of alloge-
neic T cells in MLR cultures. Mixing experiments at 1:1 ratio
signiﬁcantly suppressed the allostimulatory capacity of control
DCs. Incubation of DCs with SAHA signiﬁcantly decreased the
expression of CD40, CD80, CD86 and OX40L and but caused no
signiﬁcant changes in MHC class II expression. We determined
the in vivo relevance of SAHA mediated effects on DCs by utilizing
Class I disparate CD8mediated [bm13 2MG/], and Class II
disparate CD4 mediated [bm12 3 MHC-II/] murine models
of alloreaction. Recipient 2MG/ and Class-II/ B6 animals
received 11 Gy, 2–4 106 T cells and 5 106 TCDBM cells from
syngeneic B6 or allogeneic bm-1 and bm-12 donors respectively.
The recipients were also injected on days1 and 0 with 4–5 106
wild type B6 BM derived c-DC and s-DCs. Injection of s-DCs
signiﬁcantly reduced in vivo allogeneic donor T cell expansion of
both CD4 and CD8 T cell subsets. We next utilized the well
characterized mouse [BALB/c 3 B6] model of acute GVHD to
determine the effect of s-DCs on an ongoing GVHD reaction. On
day1, the recipient B6 animals received 11 Gy and on day 0 were
injected with 2  106 T cells and 5  106 BM cells from syngeneic
B6 or allogeneic BALB/c donors. Injection of 5  106 host type
s-DCs on days 1, 0, and 2 resulted in signiﬁcantly better
survival, reduced serum levels of TNF-, donor T cell expansion
and histopathology of GVHD (P 
 0.01) on day 7 after BMT.
Lastly, we determined the effect of SAHA on the DCs derived
from the peripheral blood of normal healthy human volunteers and
found that SAHA signiﬁcantly reduced allogeneic T cell prolifer-
ation. Together our results demonstrate that SAHA modulates
innate and allostimulatory functions of DCs in vitro and in vivo,
and suggest that SAHA treatment of DCs might represent a novel
cellular therapy that can reduce clinical GVHD.
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MATURE T CELLS ALONE SEPARATE GVL FROM GVHD: THE NEED FOR
BETTER CONTROLS
Chen, B.J.; Son, J.; Cui, X.; Chao, N.J. Duke University Medical
Center, Durham, NC.
Separation of graft-vs.-leukemia effect (GVL) from graft-vs.-host
disease (GVHD) is the phenomenon that patients with leukemia/
lymphoma achieve complete remission without GVHD after allo-
geneic stem cell transplantation. We demonstrate in this study that
separation of GVL from GVHD could be achieved using only
unmanipulated mature T cells in a mouse model. Graded numbers
(103-106) of puriﬁed T cells from C57BL/6 mice were transplanted
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